American Cancer Society
Sheldon. Boyd's Introduction to the Study of Disease, 11th edition, Lea and Febiger, 1992.
Rex et al. mifepristone - A review of it's pharmocodynamic and pharmacokinetic properties, and therapeutic potential, Drugs 45(3): 384-409, 1993.
Murphy et al. Regulation of Gene expression in T-47D human breast cancer cells by progestins and anti-progestins, human Reproduction 9 (Suppl 1): 174-180, 1994 Jun.
Romieu et al. The antiprogestin RU-486 in advanced breast cancer : preliminary clinical trial, Bulletin du Cancer 74: 455-461, 1987.
Klijn et al. Antiprogestins, a new form of endocrine therapy for human breast cancer, Cancer Research 49: 2851-2856, 1989.
Sheldon Boyd's Introduction to the study of disease, 11th Ed, Lea and Febiger, 1992
Rex et al. Mifepristone - A review of it's pharmacodynamic and pharmacokinetic properties, and therapeutic potential, Drugs 45(3) : 384-409 1993
Van der Lely et al. Successful treatment of Cushing's syndrome with the glucocorticoid antagonist RU-486, Journal of Clinical Endocrinology and Metabolism 61 : 536-540, 1985
Bertagna et al. Pituitary - adrenal response to the antiglucocorticoid action of RU-486 in Cushing's syndrome, Journal of Clinical Endocrinology and Metabolism 63 : 639-643, 1986
| 1. | Chen, Hailin; Gao, Weiguo; Lni, Shunan; Shao, Liming; Li, Ruilin (Dep.Drugs Dev.Res.Shanghai Inst. Planned Parenthood res. Shanghai, People.Rep.China). Yiyao Gongye 1986, 17 (9), 395-6. |
| 2. | Heikinheimo O, Tevilin M RU-486 in Human Plasma by HPLC and RIA after column Chromatography, contraception34; 613-624 1986 |
| 3. | Kawai S, Nieman L.K. Pharmacokinetic properties of the antiglucocoyicoid and antiprogesterone steroid RU-486 in man. Journal of pharmacology and experimental Therapeutics 241; 401-406, 1987. |
| 4. | Nagoshi K, Hayashi N. Automated direct assay system for RU-486, an antiprogesterone -anti-glucocortoid agent and its metabolites using HPLC, Acta medica Okayama 45; 81-87 1991. |
| 5. | Lahteenmaki P, Heikinheimo O et al. Pharmacokinetics and metabolism of RU-486. Journal of steroid biochemistry and molecular biology 27, 859-863, 1987. |
Endometriosis And Leiomyomas (Fibroid Tumours) [Top]
Sheldon Boyd's Introduction to the Study of Diseases, 11th Ed, Lea and Fibiger, 1992
Rex et al. Mifepristone - A review of it's pharmacodynamic and pharmacokinetic properties, and therapeutic potential, Drugs 45(3) : 384-409 1993
Wolf et al. Non-competitive antioestrogenic effect of RU-486 in blocking the oestrogen - stimulated Luteinizing hormone surge and proliferative action of estradiol on endometrium in Castrated monkeys, Fertility and Sterility 52 : 1055-1060, 1989
Kettel et al. Endocrine response to long term administration of the antiprogesterone RU-486 in patients with pelvic endometriosis, Fertility and Sterility 56 : 402-407, 1991
Murphy et al. Response of uterine fibroids to the antiprogesterone RU-486 : A pilot study , fertility and Sterility Program (Suppl) : S31, 1991
Kettel, Murphy et al. Clinical efficacy of the antiprogesterone Ru-486 in the treatment of endometriosis and uterine fibroids, Human Reproduction 9 (Suppl1), 1994
Sheldon. Boyd's Introduction to the Study of Disease, 11th Edition, Lea and Febiger, 1992.
Rex et al. Mifepristone - A review of it's pharmacodynamic and pharmacokinetic properties, and therapeutic potential, drugs 45 (3) : 384-409, 1993.
Association for Brain Tumour Research.
De Monte F. Current management of meningiomas, Oncology 9 (1): 83-91, 1996
Grunberg SM. Role of antiprogestinal therapy for meningiomas, Human Reproduction 9 (Suppll) : 202-207, 1994 Jun
Grunberg et al. Treatment of Unresectable meningiomas with the antiprogesterone agent mifepristone, Journal of Neurosurgery and Psychiatry 55: 486-490, 1992.
Hoak et al. Successful mifepristone treatment of recurrent, inoperable meningioma, Lancet 336 : 124-125, 1990
Hoak et al. Response of Meningioma to mifepristone, Europe Journal of Cancer 26: 172, 1990.
Pharmacokinetic Properties [Top]
Lahteenmaki et al. Pharmacokinetics and metabolism of RU-486, Journal of Steroid Biochemistry and Molecular Biology 27: 859-863, 1987
Rex et al. Mifepristone - A review of it's pharmacodynamic and pharmacokinetic properties, and therapeutic potential, Drugs 45 (3): 384-409, 1993
Heikinheimo et al. Metabolism and serum binding of RU-486 in women after various single doses, Human Reproduction 2: 379-385, 1987
Grimaldi et al. In Vitro study of the binding of RU-486 and RU-42633 to human serum proteins, Progress in Clinical Biological Research 300: 445-448, 1989
Deraedt et al. Pharmacokinetics of RU-486. In Baulieu & Segal (Eds) The Antiprogestin Steroid RU-486 and Human Fertility Control. Plenum Press, NY (1985) pp. 103-122
Glasier, A., Thong, J.J., Dewar, M., Mackie, M., and Baird, D.T., "Mifepristone (RU-486) compared with high-dose estrogen and progestogen for emergency postcoital contraception" The New England Journal of Medicine, 327:15, October 8, 1992, pp.1042-1044
1. Chen, Hailin; Gao, Weiguo; Lni, Shunan; Shao, Liming; Li, Ruilin (Dep.Drugs) Dev.Res. Shanghai Inst. Planned Parenthood res. Shanghai, People. Rep.China). Yiyao Gongye 1986, 17(9), 395-6